Atherosclerosis: Cell biology and lipoproteins

Current Opinion in Lipidology

Volumn 19, Issue 3, 2008, Pages 328-329

  Daugherty, Alan ^a   Rateri, Debra L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; TORCETRAPIB;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CYTOLOGY; DRUG FATALITY; DRUG TARGETING; HUMAN; IN VIVO STUDY; NOTE; PRIORITY JOURNAL;

ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; HOMEOSTASIS; HUMANS;

EID: 43249130743     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282feec55     Document Type: Note

References (8)

1. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008; 451:904-913.
2. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122.
3. Curtiss LK. Is two out of three enough for ABCG1? Arterioscler Thromb Vasc Biol 2006; 26:2175-2177.
4. Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007; 117:2216-2224. An extensive study of the relative importance of multiple proteins that can regulate the efflux of cholesterol from macrophages.
5. Wang MD, Franklin V, Marcel YL. In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. Arterioscler Thromb Vasc Biol 2007; 27:1837-1842.
6. Iwamoto N, Abe-Dohmae S, Ayaori M, et al. ATP-binding cassette transporter A1 gene transcription is downregulated by activator protein 2alpha: doxazosin inhibits activator protein 2alpha and increases high-density lipoprotein biogenesis independent of alpha1-adrenoceptor blockade. Circ Res 2007; 101:156-165. A description of the mechanism by which an off target effect of a common antihypertensive drug also benefits plasma concentrations of HDL cholesterol.
7. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-2300.
8. Weibel GL, Alexander ET, Joshi MR, et al. Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. Arterioscler Thromb Vasc Biol 2007; 27:2022-2029. A comparison effect of a native and mutant protein that promotes cholesterol efflux. This study demonstrated no difference in cholesterol efflux, despite the great effect of the mutant form on atherosclerosis.